MOONLAKE IMMUNO (MLTX)
(Delayed Data from NSDQ)
$46.05 USD
+2.99 (6.94%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $46.06 +0.01 (0.02%) 7:56 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
MoonLake Immunotherapeutics [MLTX]
Reports for Purchase
Showing records 81 - 95 ( 95 total )
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
We are initiating coverage with an OUTPERFORM rating and $33 twelvemonth PT.
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
KOL Call Reminder: Getting Under the Skin in HS & PsA
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor Data Validates Sonelokimab Approach; 2022 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Looks Favorably Positioned Against Competitor; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Phase 2 Enrollment Completed Early; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor Pivotal Data Bodes Well for Sonelokimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Timelines On Track; 3Q22 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor Trial Halt Does Not Impact Sonelokimab; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Competitor Skin Disease Data Does Not Impact Our Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Clinical Programs Advancing; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Elevating Above Competitors in IL-17 Blockade; Initiating at Buy and $28 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R